Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Albemarle Corp. (ALB) vs Eli Lilly And Co (LLY) Price & Performance

Albemarle Corp.Trade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Albemarle Corp. vs Eli Lilly And Co — how do they compare? Albemarle Corp. trades at $129.6 (market cap $15.27B), while Eli Lilly And Co trades at $1,215.96 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 70.7× Albemarle Corp.'s market cap, and Albemarle Corp. pays the higher dividend (1.27%). Which is the better fit depends on your goals.

ALBLLY
Market Cap
$15.27B$1.08T
Sector
Basic MaterialsHealth
52-Week High
$215.62$1.24K
52-Week Low
$72.58$639.43
Enterprise Value
$17.75B$1.13T
Dividend Yield
1.27%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Albemarle Corp.

Albemarle (ALB) trades at $131.21, up 0.08% on the day, showing a bullish technical trend with strong support at $129 and resistance at $133. The company reported robust Q2 2026 results, beating EPS estimates with $3.75 versus $3.20 expected, driven by improved lithium pricing and specialties growth. However, net income remains negative for 2025 at -$510.63M, and the P/E ratio is elevated at 479.11, indicating high valuation expectations. Analyst sentiment is mixed with a consensus price target of $184.50 but only 42% buy ratings.

Outlook: ALB benefits from strong lithium demand and cost controls, but faces risks from volatile lithium prices and sequential margin pressure in Q3. The stock offers growth potential if execution continues, yet high valuation and earnings inconsistency warrant caution. Near-term price action hinges on Q3 results and lithium market trends.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Albemarle Corp.

Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.

Read more on ALB

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY